KRAS and non-small cell lung carcinoma: Recently, the treatment options for NSCLC significantly improved with advancements in targeted therapies against mutated genes such as epidermal growth factor receptor (EGFR), kirsten rat sarcoma viral oncogene (KRAS), and anaplastic lymphoma kinase (ALK) [29, 30].